Sign up
Pharma Capital

Cosmos Holdings pays off all its convertible debt

CEO Gregory Siokas said that with the acquisition of Athens-based Cosmofarm and the note repayment, the company is ‘well-positioned' for growth in 2019
Pills spilling out from a vial
Cosmos Holdings specializes in acquiring, developing, and commercializing medicines and has offices and distribution centers in Thessaloniki, Greece and in the UK

Cosmos Holdings Inc (OTCQB:COSM) announced Wednesday that the international pharmaceutical company has paid off the remaining balance of its convertible notes.

The aggregate initial principal amounts of the notes totaled $5,583,333.

"We are excited to announce the repayment of all our convertible debt,” said Cosmos Holdings CEO Gregory Siokas. “With the acquisition of Cosmofarm that closed in December of last year, and this note repayment, we believe are well-positioned for growth in 2019." 

READ: Cosmos posts 3Q profit and strong profit margins on booming drug sales and bolstered balance sheet

Established in 1994, Cosmofarm is a pharmaceutical wholesale company in Athens, which provides a comprehensive range of products. Its core business focuses on sourcing and distributing branded and generic medicines, over-the-counter pharmaceuticals, food supplements and medical devices to more than 1,130 pharmacies.

Cosmofarm conducts business with as many as 250 pharmaceutical manufacturers and wholesalers and reported sales of about $14 million for the 2017 fiscal year.

Cosmos Holdings specializes in acquiring, developing, and commercializing medicines. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece and in the UK.

Shares in Cosmos Holdings traded flat at $2.89.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 



Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.